ID: ALA28049

Max Phase: Preclinical

Molecular Formula: C20H25N9O3

Molecular Weight: 439.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCCN)C(=O)O)cc1

Standard InChI:  InChI=1S/C20H25N9O3/c1-29(10-12-9-24-17-15(25-12)16(22)27-20(23)28-17)13-6-4-11(5-7-13)18(30)26-14(19(31)32)3-2-8-21/h4-7,9,14H,2-3,8,10,21H2,1H3,(H,26,30)(H,31,32)(H4,22,23,24,27,28)/t14-/m0/s1

Standard InChI Key:  XZMFYMLGNMSYOG-AWEZNQCLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 439.48

Molecular Weight (Monoisotopic): 439.2080

AlogP: 0.14

#Rotatable Bonds: 9

Polar Surface Area: 199.26

Molecular Species: ZWITTERION

HBA: 10

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 12

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.38

CX Basic pKa: 9.90

CX LogP: -2.49

CX LogD: -2.49

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.30

Np Likeness Score: -0.51

References

1. Rosowsky A, Bader H, Kohler W, Freisheim JH, Moran RG..  (1988)  Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.,  31  (7): [PMID:2898531] [10.1021/jm00402a014]

Source

Source(1):

• Scientific Literature